Markets
Korsana Biosciences has emerged from stealth with US$175m to develop an Alzheimer’s antibody designed to boost amyloid plaque clearance. The Waltham, Massachusetts-based biotech is focused on neurodegenerative disease. Its lead programme, KRSA-028, is a next-generation shuttled monoclonal antibody targeting amyloid beta, a protein that can build up into plaques in Alzheimer’s. The treatment uses the [...]
Regenerative innovator's cash boost, are biological clocks out of time?, Y chromosome concerns, £60bn of graft by UK pensioners Indian regenerative medicine company Pandorum Technologies, has raised US$18m in a Series B funding round to support its clinical developments and global expansion. The company, which operates the United States as well as its domestic market, [...]
GSK has signed a five-year deal with JAX-NYSCF to build stem cell models for neurodegenerative disease, with Alzheimer’s a key target. The collaboration with The Jackson Laboratory-New York Stem Cell Foundation Collaborative aims to combine human stem cell research with large-scale research systems to help bridge discovery and drug development. The partners plan to develop [...]
Long-term gut health and female finance, London likes longevity New York innovator Salvo Health has secured $8.5m in Series A round as it looks to develop new, long-term, gut-health treatments. The funding round was led by ManchesterStory, City Light Capital and Threshold Ventures, with additional support from The Artemis Fund, Owl Capital, Impact X Capital [...]
Bryan Johnson has launched a US$1m-a-year longevity programme with just three places, offering access to the exact protocol he has followed for five years. The programme, called "Immortals", is offered by the former fintech entrepreneur, now a prominent and often controversial figure in longevity. Johnson’s unconventional methods have included Botox injections in his genitals (Botox [...]
A French biotech has raised €12m to test whether GLP-1 drugs can modify osteoarthritis progression. The funding will advance 4Moving Biotech's lead programme, 4P004, toward a phase 2a proof-of-concept readout in knee osteoarthritis, a joint disease that causes pain and stiffness. Despite affecting more than 600 million people worldwide, no therapy approved in Europe or [...]
Harbor Health has acquired dementia care startup Rippl; terms were not disclosed. Founded in 2021, Rippl provides specialised dementia care and support, including personalised care plans, medication assessments and 24/7 access to care navigators and licensed clinicians. The Seattle-based company aims to help seniors with dementia stay at home and reduce emergency department visits. It [...]
Longevity startup Biopeak has secured US$2.7m in a follow-on funding round. Founded in 2025 by Rishi Pardal and Shiva Subramanian, Biopeak operates India’s first specialised brand aimed at extending lifespans through preventive care. The company opened a clinic in Bengaluru last year and plans to open a second one in the coming month. The funds [...]
Biotechnology company Aerska has raised US$39m in Series A funding to develop brain-delivered RNA medicines. The company is developing treatments for neurological diseases, including genetically driven forms of Alzheimer's disease. This takes Aerska's total funding to US$60m, months after its seed funding announcement in October 2025. The company's platform uses what it calls "brain shuttle" [...]
Novo Nordisk will launch an Ozempic pill for diabetes in select doses in the second quarter of this year. The Danish drugmaker said the US Food and Drug Administration has approved Ozempic tablets in 1.5 milligram, 4 milligram and 9 milligram doses. The new Ozempic branding is intended to help patients and healthcare professionals more [...]
